ES2518340T3 - Composiciones farmacéuticas para tratar enfermedades asociadas con la actividad de NF-kappaB - Google Patents

Composiciones farmacéuticas para tratar enfermedades asociadas con la actividad de NF-kappaB Download PDF

Info

Publication number
ES2518340T3
ES2518340T3 ES05838184.9T ES05838184T ES2518340T3 ES 2518340 T3 ES2518340 T3 ES 2518340T3 ES 05838184 T ES05838184 T ES 05838184T ES 2518340 T3 ES2518340 T3 ES 2518340T3
Authority
ES
Spain
Prior art keywords
nik
antibody
activity
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05838184.9T
Other languages
English (en)
Spanish (es)
Inventor
David Wallach
Parameswaran Ramakrishnan
Taisa Shmushkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2518340T3 publication Critical patent/ES2518340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES05838184.9T 2004-12-27 2005-12-11 Composiciones farmacéuticas para tratar enfermedades asociadas con la actividad de NF-kappaB Expired - Lifetime ES2518340T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16600604 2004-12-27
IL16600604A IL166006A0 (en) 2004-12-27 2004-12-27 Pharmaceutical compositions for treating diseases associated with nf-kb activity
PCT/IL2005/001335 WO2006070348A1 (en) 2004-12-27 2005-12-11 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-κB ACTIVITY

Publications (1)

Publication Number Publication Date
ES2518340T3 true ES2518340T3 (es) 2014-11-05

Family

ID=36072106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05838184.9T Expired - Lifetime ES2518340T3 (es) 2004-12-27 2005-12-11 Composiciones farmacéuticas para tratar enfermedades asociadas con la actividad de NF-kappaB

Country Status (9)

Country Link
US (1) US8338567B2 (enExample)
EP (1) EP1838347B1 (enExample)
JP (1) JP5686940B2 (enExample)
AU (1) AU2005320905B2 (enExample)
CA (1) CA2593035C (enExample)
ES (1) ES2518340T3 (enExample)
IL (2) IL166006A0 (enExample)
NO (1) NO20073942L (enExample)
WO (1) WO2006070348A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954728B2 (ja) 2010-01-22 2016-07-20 国立研究開発法人科学技術振興機構 蛋白質の分解活性を測定するためのプローブ試薬
EP3431493A1 (en) * 2013-09-03 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for inducing senescence in cancer
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5843721A (en) 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
US6265538B1 (en) * 1998-02-27 2001-07-24 The Regents Of The University Of California Inhibitor of the inflammatory response induced by the TNFA and IL-1
ITMI20010402U1 (it) 2001-07-18 2003-01-18 Valerio Leccacorvi Rivestimento per le superfici di una piscina
ATE521707T1 (de) * 2002-04-18 2011-09-15 Yeda Res & Dev Derivate eines nf-kappab induzierenden enzyms, verfahren zur herstellung der derivate und deren verwendung

Also Published As

Publication number Publication date
JP5686940B2 (ja) 2015-03-18
JP2008525427A (ja) 2008-07-17
US20090098106A1 (en) 2009-04-16
NO20073942L (no) 2007-09-27
IL183926A0 (en) 2007-10-31
CA2593035A1 (en) 2006-07-06
AU2005320905B2 (en) 2011-03-17
US8338567B2 (en) 2012-12-25
IL183926A (en) 2012-02-29
EP1838347A1 (en) 2007-10-03
AU2005320905A1 (en) 2006-07-06
WO2006070348A1 (en) 2006-07-06
IL166006A0 (en) 2006-01-15
CA2593035C (en) 2014-10-14
EP1838347B1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
Chiu et al. Hypoxia induces myeloid‐derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C‐C motif) ligand 26
Blencowe et al. A coactivator of pre-mRNA splicing
US9316654B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
US20160051674A1 (en) Methods and pharmaceutical compositions (ctps 1 inhibitors, e.g. norleucine) for inhibiting t cell proliferation in a subject in need thereof
JP2011506274A (ja) ファスチンを阻害するための方法
EP2134373A2 (en) Nuclear targeting sequences
Hao et al. miRNA-186-5p inhibits migration, invasion and proliferation of breast cancer cells by targeting SBEM
ES2469670T3 (es) Métodos y agentes para inmunomodulaci�n y métodos para identificar inmunomoduladores
AU2008287555A1 (en) VHZ for diagnosis and treatment of cancer
CA2586987A1 (en) Methods and compositions for treating cellular proliferative diseases
ES2518340T3 (es) Composiciones farmacéuticas para tratar enfermedades asociadas con la actividad de NF-kappaB
WO2003035048A2 (en) Methods for the treatment of osteoarthritis and compositions thereof
US20050250186A1 (en) Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
CN101558307A (zh) 抑制mphosph1与prc1之间的结合的作用剂的筛选方法
US20080305102A1 (en) Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer
US20050186600A1 (en) Polynucleotides encoding novel UbcH10 polypeptides and kits and methods using same
JP2007282628A (ja) 抗癌剤のスクリーニング方法
CN102690866A (zh) Trpm7基因及其表达产物的应用
KR20190062149A (ko) 전이성 암 치료용 조성물
WO2006070804A1 (ja) テロメレース活性阻害方法および阻害剤
US20230288399A1 (en) Method for screening colorectal cancer metastasis inhibitor
ES2365712T3 (es) Anticuerpos contra nik, su preparación y su uso.
WO2016141297A2 (en) Compositions and methods for inhibiting cell proliferation
US20100113557A1 (en) Method for prevention of tumor
Hua Regulation of initiation of DNA replication in Xenopus egg extract